Form 4: Alnylam Pharmaceuticals CEO Yvonne Greenstreet Executes Stock Option and Sells Shares Under 10b5-1 Plan

Alnylam Pharmaceuticals CEO Yvonne Greenstreet exercised stock options and sold 15,000 shares of common stock on August 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 20, 2024, Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, exercised a stock option to acquire 15,000 shares of common stock at a price of $85 per share.
• Simultaneously, Greenstreet sold 15,000 shares of Alnylam common stock at $280 per share.
• These transactions were executed under a Rule 10b5-1(c) trading plan adopted on March 12, 2024.
• Following these transactions, Greenstreet directly owns 73,441 shares of Alnylam common stock.
• Greenstreet also indirectly owns 407 shares through a managed account and 2,352 shares through stock options.
• The stock option exercised was fully vested and exercisable as of February 28, 2023, with an expiration date of February 27, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned strategy, but the sale of shares could still create some uncertainty among investors.

Positives

• The CEO's actions are in accordance with a pre-arranged trading plan, which can reassure investors that the transactions are not based on insider information.
• The exercise of stock options demonstrates the CEO's belief in the company's long-term value.

Negatives

• The sale of shares by the CEO, even under a pre-arranged plan, could be perceived negatively by some investors.

Risks

• While the transactions are under a 10b5-1 plan, market perception could still be affected by the CEO's sale of shares.
• Changes in market conditions could impact the effectiveness of the 10b5-1 plan.

Future Outlook

The document does not contain specific forward-looking statements, but the CEO's continued ownership of shares and participation in the 401(k) plan suggest a continued commitment to the company.

Industry Context

Insider transactions are common in the pharmaceutical industry, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Comparing Greenstreet's transactions to those of CEOs at similar biotech companies like Moderna (MRNA) or BioNTech (BNTX) would provide context.
• For example, if other CEOs are also selling shares under 10b5-1 plans, it could indicate a broader trend in the industry.
• Conversely, if Greenstreet's sales are significantly larger than those of her peers, it could raise concerns.

Stakeholder Impact

• Shareholders may react to the CEO's sale of shares, although the 10b5-1 plan mitigates concerns about insider information.
• Employees may view the CEO's actions as a reflection of the company's prospects.

Key Dates